CompanyINBXNasdaqLa Jolla, CA

Inhibrx Biosciences, Inc

Inhibrx Biosciences develops biologic therapeutics using protein engineering platforms.

SEC EDGAR ClinicalTrials.gov inhibrx.com

8-KSep 28Latest SEC filing

Sep 8Latest story

September 2026

Inhibrx reports Phase 2 HNSCC data showing INBRX-106 combo nearly doubles response rate

Sep 8Clinical readoutInhibrx Biosciences, Inc

August 2026

Inhibrx reports Q2 2026 results, sets Q3 PFS readout for INBRX-106

Aug 13Quarterly updateInhibrx Biosciences, Inc

July 2026

Inhibrx Biosciences announces $500 million Oxford Finance credit facility, publicly discloses terms

Jul 16FinancingInhibrx Biosciences, Inc